The present invention is directed to expression vectors comprising a polynucleotide that encodes a human telomerase reverse transcriptase (hTRT) protein, variant, or fragment. The present invention is also directed to host cells that comprise expression vectors comprising a polynucleotide that encod
The present invention is directed to expression vectors comprising a polynucleotide that encodes a human telomerase reverse transcriptase (hTRT) protein, variant, or fragment. The present invention is also directed to host cells that comprise expression vectors comprising a polynucleotide that encodes a hTRT protein variant, or fragment.
대표청구항▼
1. A recombinant expression vector containing a polynucleotide that comprises an encoding region for a telomerase reverse transcriptase protein, variant, or fragment,wherein the protein, variant or fragment has telomerase catalytic activity when complexed with a telomerase RNA, and wherein a single-
1. A recombinant expression vector containing a polynucleotide that comprises an encoding region for a telomerase reverse transcriptase protein, variant, or fragment,wherein the protein, variant or fragment has telomerase catalytic activity when complexed with a telomerase RNA, and wherein a single-stranded DNA consisting of said encoding region hybridizes to a second single-stranded DNA at 5° C. to 25° C. below Tm in aqueous solution at 1 M NaCl, wherein said second DNA is exactly complementary to SEQ. ID NO:224, and Tm is the melting temperature under the same reaction conditions of double-stranded DNA having the sequence of SEQ. ID NO:224. 2. The expression vector of claim 1, further comprising a promoter, an enhancer, or a 3′ untranslated region.3. The expression vector of claim 1, selected from a recombinant bacteriophage, a plasmid, a cosmid, a yeast expression vector, and a viral expression vector.4. The expression vector of claim 1, selected from a mammalian virus expression vector, an SV40 virus expression vector, an EBV expression vector, an Autographa californica nuclear polyhedrosis virus expression vector, an adenovirus expression vector, a retrovirus expression vector, a herpes virus expression vector, and a vaccinia virus expression vector.5. The expression vector of claim 2, wherein the promoter is a constitutive promoter.6. The expression vector of claim 2, wherein the promoter is an inducible promoter.7. The expression vector of claim 2, wherein the promoter is selected from an alpha factor promoter, an alcohol oxidase promoter, a PGH promoter, a 35S promoter of CaMV, a 19S promoter at CaMV, a lacZ promoter, a ptrp-lac hybrid promoter, a polyhedrin promoter, a heat shock promoter, a RUBISCO promoter, and a storage protein gene promoter.8. The expression vector of claim 1, further comprising a viral origin of replication.9. The expression vector of claim 1, further comprising a selectable marker gene.10. The expression vector of claim 9, wherein the selectable marker gene is selected from herpes simplex virus thymidine kinase, adenine phosphoribosyltransferase, dhfr, npt, ala, pat, trpB, hisD, anthocyanin, β-glucuronidase, and luciferase.11. A host cell comprising the expression vector of claim 1.12. A host cell comprising the expression vector of claim 2.13. A host cell comprising the expression vector of claim 3.14. A host cell comprising the expression vector of claim 4.15. An expression vector containing a polynucleotide that comprises an encoding region for a polypeptide containing SEQ. ID NO:225, or fragment thereof that has telomerase catalytic activity when complexed with a telomerase RNA.16. The expression vector of claim 15, which is an adenovirus expression vector, a retrovirus expression vector, a herpes virus expression vector, or a vaccinia virus expression vector.17. The expression vector of claim 15, further comprising a constitutive or inducible promoter operably linked to the encoding region.18. The expression vector of claim 15, which causes expression at telomerase reverse transcriptase in mammalian cells.19. The expression vector of claim 15, in a composition that comprises a pharmaceutically acceptable carrier.20. A host cell comprising the expression vector of claim 15.
Thomas R. Cech ; Joachim Lingner CH; Toru Nakamura ; Karen B. Chapman ; Gregg B. Morin ; Calvin B. Harley ; William H. Andrews, Antisense compositions for detecting and inhibiting telomerase reverse transcriptase.
Cech, Thomas R.; Lingner, Joachim; Nakamura, Toru; Chapman, Karen B.; Morin, Gregg B.; Harley, Calvin B.; Andrews, William H., Cells immortalized with telomerase reverse transcriptase for use in drug screening.
Thomas R. Cech ; Joachim Lingner CH; Toru Nakamura ; Karen B. Chapman ; Gregg B. Morin ; Calvin B. Harley ; William H. Andrews, Human telomerase catalytic subunit: diagnostic and therapeutic methods.
Mullis Kary B. (La Jolla CA) Erlich Henry A. (Oakland CA) Gelfand David H. (Oakland CA) Horn Glenn (Emeryville CA) Saiki Randall K. (Richmond CA), Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Diamond Paul (693 Somerville Ave. ; Apt. 4 Somerville MA 02143), Screening assay for inhibitors and activators of RNA and DNA-dependent nucleic acid polymerases.
West Michael D. (Belmont CA) Shay Jerry (Dallas TX) Wright Woodring (Arlington TX), Therapy and diagnosis of conditions related to telomere length and/or telomerase activity.
Cech, Thomas R.; Lingner, Joachim; Nakamura, Toru M.; Chapman, Karen B.; Morin, Gregg B.; Harley, Calvin B.; Andrews, William H., Method for eliciting an immune response to human telomerase reverse transcriptase.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.